Illumina, Inc. (ILMN) SVP Sells $3,118,400.00 in Stock

Illumina, Inc. (NASDAQ:ILMN) SVP Mostafa Ronaghi sold 10,000 shares of the company’s stock in a transaction on Wednesday, October 10th. The stock was sold at an average price of $311.84, for a total value of $3,118,400.00. Following the sale, the senior vice president now owns 80,805 shares of the company’s stock, valued at $25,198,231.20. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Mostafa Ronaghi also recently made the following trade(s):

  • On Monday, September 10th, Mostafa Ronaghi sold 10,000 shares of Illumina stock. The shares were sold at an average price of $347.07, for a total value of $3,470,700.00.
  • On Friday, August 10th, Mostafa Ronaghi sold 10,000 shares of Illumina stock. The shares were sold at an average price of $331.39, for a total value of $3,313,900.00.

Shares of ILMN opened at $321.69 on Friday. Illumina, Inc. has a 1 year low of $198.21 and a 1 year high of $372.61. The company has a quick ratio of 2.44, a current ratio of 2.74 and a debt-to-equity ratio of 0.22. The stock has a market cap of $53.96 billion, a PE ratio of 80.42, a P/E/G ratio of 3.04 and a beta of 0.97.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Monday, July 30th. The life sciences company reported $1.43 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.11 by $0.32. Illumina had a return on equity of 26.64% and a net margin of 20.88%. The company had revenue of $830.00 million during the quarter, compared to the consensus estimate of $786.88 million. During the same period last year, the company earned $0.82 earnings per share. The firm’s revenue was up 25.4% compared to the same quarter last year. On average, research analysts anticipate that Illumina, Inc. will post 5.46 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently modified their holdings of ILMN. Cadence Capital Management LLC grew its stake in Illumina by 3.6% during the second quarter. Cadence Capital Management LLC now owns 4,702 shares of the life sciences company’s stock worth $1,313,000 after purchasing an additional 162 shares during the period. Sumitomo Mitsui Asset Management Company LTD grew its stake in Illumina by 1.8% during the second quarter. Sumitomo Mitsui Asset Management Company LTD now owns 10,241 shares of the life sciences company’s stock worth $2,860,000 after purchasing an additional 179 shares during the period. Private Asset Management Inc. grew its stake in Illumina by 1.6% during the second quarter. Private Asset Management Inc. now owns 11,243 shares of the life sciences company’s stock worth $3,140,000 after purchasing an additional 180 shares during the period. Northwestern Mutual Wealth Management Co. grew its stake in Illumina by 12.9% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 1,627 shares of the life sciences company’s stock worth $454,000 after purchasing an additional 186 shares during the period. Finally, Dempze Nancy E grew its stake in Illumina by 3.7% during the second quarter. Dempze Nancy E now owns 5,432 shares of the life sciences company’s stock worth $1,517,000 after purchasing an additional 194 shares during the period. Institutional investors own 89.84% of the company’s stock.

Several research firms have commented on ILMN. UBS Group began coverage on Illumina in a research report on Tuesday. They issued a “neutral” rating and a $340.00 target price for the company. Barclays increased their target price on Illumina from $300.00 to $350.00 and gave the company an “overweight” rating in a research report on Tuesday, July 31st. Citigroup increased their target price on Illumina from $330.00 to $345.00 and gave the company a “buy” rating in a research report on Tuesday, July 31st. Bank of America increased their target price on Illumina from $345.00 to $370.00 and gave the company a “buy” rating in a research report on Tuesday, July 31st. Finally, Piper Jaffray Companies increased their target price on Illumina from $272.00 to $329.00 and gave the company an “overweight” rating in a research report on Tuesday, July 17th. Five analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $324.76.

About Illumina

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.

See Also: What is Considered a Good Return on Equity (ROE)?

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply